Tim MacDonald1,2,3* and Adrian Dunlop4
1Currumbin Clinic, Australia
2Griffith University School of Medicine, Australia
3John Flynn Private Hospital, Australia
4Newcastle Community Health Centre, Australia
Introduction and Aims: Lisdexamfetamine is a long acting dopamine and noradrenaline agonist approved for the indication of Attention-Deficit Hyperactivity Disorder in Australia. There is evidence it may minimize symptoms of Binge Eating Disorder and Narcolepsy. As a prodrug, it has less abuse liability due to the rate limiting hydrolysing reaction in red cells to produce Dexamphetamine. Lisdexamfetamine is currently being examined as a potential agonist therapy for Methamphetamine Dependence/Stimulant Use Disorder. Design and
Methods: Patients were retrospectively selected from a cohort of inpatients and outpatients from a single hospital site. Selection criteria were neuroadaptation with Methamphetamine, and the use of pharmacotherapy with Lisdexamfetamine.
Results: 10 patients with Stimulant Use Disorder were treated with low dose Lisdexamfetamine, with varying degrees of clinical success. Any positive treatment effect was lost immediately after cessation of therapy. Illicit drug monitoring and treatment compliance were problematic. One male patient had an exacerbation of a co-existing psychotic disorder. All of the patients selected for inclusion in this case series had Attention-Deficit Hyperactivity Disorder according to DSM-5 criteria.
Methamphetamine; Lisdexamfetamine; Stimulant; Dopamine agonists; Craving
MacDonald T, Dunlop A. Repurposing Low Dose Lisdexamfetamine as Agonist Therapy for Stimulant Use Disorder: Case Series. World J Psychiatry Ment Health Res. 2018; 2(1): 1007.